BIB icon

ProShares Ultra NASDAQ Biotechnology
BIB

Overview Fund Activity

24 hedge funds and large institutions have $5.59M invested in ProShares Ultra NASDAQ Biotechnology in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
24
Holders Change
-4
Holders Change %
-14.29%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
6
Closed
9
Calls
$1.57M
Puts
$2.38M
Net Calls
-$812K
Net Calls Change
+$52K

Top Buyers

1
Citadel Advisors
1
Citadel Advisors
Florida
$2.43M
2
TRCT
2
Tower Research Capital (TRC)
New York
$681K
3
Jane Street
3
Jane Street
New York
$290K
4
Bank of America
4
Bank of America
North Carolina
$19K
5
Qube Research & Technologies (QRT)
5
Qube Research & Technologies (QRT)
United Kingdom
$12K

Top Sellers

1
OMC
1
Old Mission Capital
Illinois
$0
2
JF
2
Jump Financial
Illinois
$0
3
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$727K
4
TCM
4
Traynor Capital Management
Pennsylvania
$0
5
Koshinski Asset Management
5
Koshinski Asset Management
Illinois
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
Koshinski Asset Management
26
Koshinski Asset Management
Illinois
– -$276K -4,454 Closed
Walleye Capital
27
Walleye Capital
New York
– -$275K -4,433 Closed
Vontobel Holding
28
Vontobel Holding
Switzerland
– -$206K -3,321 Closed
Osaic Holdings
29
Osaic Holdings
Arizona
– -$12K -200 Closed
GWM
30
Geneos Wealth Management
Colorado
– -$6K -100 Closed
AW
31
Avion Wealth
Texas
– -$4K -62 Closed
1
2